克罗恩病的生物治疗

Biological therapy in Crohn's disease.

作者信息

Gordon J N, MacDonald T T

机构信息

Division of Infection, Inflammation, and Repair, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD.

出版信息

Hosp Med. 2003 Dec;64(12):708-12. doi: 10.12968/hosp.2003.64.12.2361.

DOI:10.12968/hosp.2003.64.12.2361

PMID:14702781

Abstract

The discovery of the central role of tumour necrosis factor-alpha in Crohn's disease and the subsequent introduction of infliximab into routine clinical practice has transformed the treatment of refractory disease. Advances in understanding of the immunopathological basis of Crohn's disease are leading to the development of new biological therapies which are likely to play an increasing role in future.

摘要

肿瘤坏死因子-α在克罗恩病中的核心作用的发现以及随后英夫利昔单抗引入常规临床实践，改变了难治性疾病的治疗方式。对克罗恩病免疫病理基础认识的进展正促使新生物疗法的开发，这些疗法可能在未来发挥越来越重要的作用。